Westchester’s Regeneron Pharmaceuticals Will Spend $800M to Expand Upstate
John Jordan | September 2018
ALBANY—Tarrytown-based Regeneron Pharmaceuticals Inc. is at it again, but this time in the Capital District. The state’s largest biotechnology company is planning to spend $800 million to expand its research and lab facilities upstate outside of Albany.
The company’s capital plans were announced on Tuesday by Gov. Andrew Cuomo, who reported that the state’s Empire State Development Corp. has offered Regeneron up to $140 million in performance-based incentives, including $70 million in Excelsior Jobs Program tax credits in connection with its latest expansion project.
The $800-million will be spent over the next seven years to expand its laboratory space, manufacturing capacity and warehouse facilities at the company’s Rensselaer County campus. The expansion program will create 1,500 new full-time jobs in the greater Capital Region.
“New York is proud to be at the forefront of the life sciences industry and the home of global biotech leaders like Regeneron,” Gov. Cuomo said. “The continued growth of Regeneron here in New York is yet another indication that we are leading the way in the life sciences and attracting the jobs of tomorrow. Regeneron’s expansion will further drive economic growth in the Capital Region and fuel lifesaving innovation and development that benefits the entire world.”
Regeneron reports that the bulk of its investment will involve expansion projects at its Tempel Lane campus in East Greenbush. The firm plans to develop 240,000 square feet of office and lab space, 350,000 square feet of manufacturing space and a 1,000-space parking garage. Additional expansion projects will also include renovations and a new parking lot at its One Global Way facilities in Troy, NY and infrastructure upgrades, additional parking and office space and possible expansion of its manufacturing operations at its Red Mill campus in Rensselaer, NY.
In the last seven years, Regeneron has spent $200 million to expand operations in Rensselaer County and currently employs more than 2,500 workers there.
Leonard S. Schleifer, M.D., Ph.D., president and CEO of Regeneron, said, “As our number of approved and investigational medicines continues to grow, our need for world-class manufacturing teams and facilities also increases. These state incentives, along with other state and federal policies, have helped Regeneron keep and expand our operations in New York State, which will benefit the local economy and help us achieve our mission of bringing new medicines to people with serious diseases.”
Regeneron has over the past few years undertaken a host of expansion projects at its corporate headquarters in Tarrytown and also secured approvals for future expansion on adjoining land in the Town of Greenburgh.
In November 2017 the Town Board of Greenburgh approved the site plan application of Regeneron Pharmaceuticals for a new research and development campus on a portion of a 100-acre parcel in the northern section of the town.
The project could eventually involve the development of up to nine buildings totaling more than 1 million square feet of research and development and related spaces at the property. Also, in 2017, Regeneron acquired its 1.5-million-square-foot corporate headquarters campus the Landmark at Eastview from an affiliate of BioMed Realty Inc. for $750 million.
In July of this year Gov. Cuomo announced a new public-private research collaboration to advance the diagnosis and treatment of tick-borne diseases. The New York State Department of Health Wadsworth Center Laboratory and Regeneron will collaborate to potentially develop improved diagnostics, prophylactics, and therapeutics for the diagnosis and treatment of tick-borne diseases, starting with Lyme disease.
Regeneron and the Wadsworth Center Laboratory will jointly research how the causative agent of Lyme disease, the bacterium Borrelia burgdorferi, replicates when a human is bitten by a tick carrying the bacterium, and how the host’s immune response is activated. This information will potentially advance the development of improved diagnostics, prophylactics, and new therapeutics. Over the course of five years, Regeneron will invest up to $48 million in this research and the state will reimburse 50% of Regeneron’s research costs up to a total reimbursement of $24 million through the New York State Life Sciences Initiative. Additionally, up to $6 million will be provided to Wadsworth Center Laboratory through the Life Sciences Initiative.